Q4 EPS Estimate for Amicus Therapeutics Boosted by Analyst

Amicus Therapeutics, Inc. (NASDAQ:FOLDFree Report) – Equities research analysts at Leerink Partnrs lifted their Q4 2024 earnings per share estimates for Amicus Therapeutics in a research note issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter, up from their prior forecast of ($0.04). The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics’ Q1 2025 earnings at ($0.05) EPS.

Several other equities analysts have also recently commented on FOLD. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Bank of America increased their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Guggenheim lifted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.88.

Read Our Latest Stock Analysis on Amicus Therapeutics

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $9.65 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics has a 1-year low of $8.78 and a 1-year high of $14.03. The firm has a 50-day moving average of $9.63 and a two-hundred day moving average of $10.51. The stock has a market cap of $2.88 billion, a P/E ratio of -28.38, a PEG ratio of 1.53 and a beta of 0.62.

Institutional Trading of Amicus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. OLD Second National Bank of Aurora purchased a new stake in Amicus Therapeutics in the 3rd quarter worth about $26,000. Hazlett Burt & Watson Inc. increased its stake in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the period. Blue Trust Inc. lifted its position in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at $55,000.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $11.46, for a total value of $85,950.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $10,161,054.84. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 22,901 shares of company stock valued at $259,863 in the last quarter. Corporate insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

(Get Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Featured Articles

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.